Researchers Seek Ways to Minimize Off-Target Effects
Literature Review: Dials for Cas9
Methods to Control Cas9-Based Technologies Across Numerous Dimensions Is Still Lacking
Opening Up Relieves Downstream Bottlenecks
Celebrate the Downstream Improvements That Have Been Achieved, Even If They Fail to Match Upstream Improvements
Top 10 European Biopharma Clusters
The Continent’s Key Academic and Industrial Centers for Drug Development
Search Results for
Neuro Drug Developer Ovid Therapeutics Files for $86M IPO
April 12, 2017
The company is licensing the rare pediatric epilepsy candidate from Takeda Pharmaceutical ... According to the IPO filing, Takeda received 3,831,293 shares of Ovid through the ...
Takeda, NuBiyota Partner on Oral Microbiome Therapeutics for...
April 11, 2017
GEN News Highlights More » April 11, 2017 Takeda, NuBiyota Partner on Oral Microbiome Therapeutics for Gastroenterology Takeda Pharmaceutical Company and NuBiyota are partnering ...
Takeda to Develop Finch's Microbiome Therapeutic for IBD
April 5, 2017
GEN News Highlights More » April 5, 2017 Takeda to Develop Finch's Microbiome Therapeutic for IBD Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global ...
Takeda Slicing Ariad Workforce After Acquisition
March 30, 2017
GEN News Highlights More » March 30, 2017 Takeda Slicing Ariad Workforce After Acquisition Takeda Pharmaceutical has absorbed only part of the nearly 300-employee workforce it ...
Icahn Names Gene Transfer Pioneer as Portfolio Manager
March 3, 2017
M.D., into retirement from the helm of Ariad Pharmaceuticals, the cancer drug developer that he founded in 1991 and is being acquired by Takeda Pharmaceutical for $5.2 billion. Dr. ...
Karyopharm Says Lead Candidate Likely to Fail Phase II Trial...
March 3, 2017
... This year, Karyopharm plans to launch a Phase III combination study of selinexor with Takeda-marketed bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in multiple myeloma ...
Incyte Partners with Penn on Cancer Immunotherapy Research |...
February 23, 2017
... The company also licenses European rights to the leukemia drug Iclusig® (ponatinib) from Ariad Pharmaceuticals, which is being acquired by Takeda Pharmaceutical. To enjoy more ...
Takeda to Support Koch Institute Immuno-Oncology Research with...
February 8, 2017
GEN News Highlights More » February 8, 2017 Takeda to Support Koch Institute Immuno-Oncology Research with $1M Gift Takeda Pharmaceutical has given a two-year, $1 million gift to ...
Maverick Licenses Isogenica's Synthetic Camelid Antibody Platform...
February 7, 2017
Last month Maverick signed a potentially $125 collaboration with Takeda that could see the Japanese drugs giant acquire Maverick after 5 years. Synthetic antibody library ...
Top 10 Wall Street Winners of 2016
February 6, 2017
jumping nearly 116% before announcing on January 9 that it is being acquired by Takeda Pharmaceutical for approximately $5.2 billion. #10. Argos Therapeutics NASDAQ: ARGS ...